EDGAR·FLOW

Lakewood-Amedex Biotherapeutics Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 92/100
What the filing says
Lakewood-Amedex Biotherapeutics Inc. (total assets ~$5.0M) filed an 8-K on 2026-11-16 disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific details regarding which exchange issued the notice, the reason for non-compliance, timeline for cure, or any remediation plan. Only the fact of the delisting notice is disclosed; financial impact and next steps are not specified in this document.
Why this rating

Delisting is existential threat to small-cap biotech; eliminates public market access, liquidity, and credibility—catastrophic for $5M company.

Extracted items
Tradability signal
NO TRADE

No trade: price $0.21 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$0.23 ▲ 11.63%
at our read · unknown
$0.21
+10 min · unknown
$0.21 ▲ 4.22%
+30 min · unknown
$0.23 ▲ 11.59%
+1 hr · unknown
$0.24 ▲ 18.66%
+4 hrs · unknown
$0.24 ▲ 17.01%

The stock had already moved -10.42% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ LABT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.